Assignee
INT INST CANCER IMMUNOLOGY INC
JP·36 granted patents·15 pending applications·308 citations·filing 2003–2022
Top patents by PatentIndex Score
51 records- 0196US7622119B2Cancer antigen peptides derived from WT1INT INST CANCER IMMUNOLOGY INC·Filed 2005·Granted Nov 24, 2009·33 cites·10 claims
- 0296US7608685B1Tumor antigen based on products of the tumor suppressor gene WT1INT INST CANCER IMMUNOLOGY INC·Filed 2005·Granted Oct 27, 2009·38 cites·9 claims
- 0396US7517950B2Tumor antigen based on products of the tumor suppressor gene WT1INT INST CANCER IMMUNOLOGY INC·Filed 2006·Granted Apr 14, 2009·35 cites·9 claims
- 0495US7666985B2HLA-A24-restricted cancer antigen peptidesINT INST CANCER IMMUNOLOGY INC·Filed 2008·Granted Feb 23, 2010·31 cites·4 claims
- 0595US7390871B2Tumor antigen based on products of the tumor suppressor gene WT1INT INST CANCER IMMUNOLOGY INC·Filed 2005·Granted Jun 24, 2008·24 cites·9 claims
- 0693US7939627B2Peptides comprising an epitope of the wilms tumor gene productINT INST CANCER IMMUNOLOGY INC·Filed 2006·Granted May 10, 2011·21 cites·11 claims
- 0793US7807792B2Tumor antigen based on products of the tumor suppressor gene WT1INT INST CANCER IMMUNOLOGY INC·Filed 2009·Granted Oct 5, 2010·15 cites·12 claims
- 0892US8968745B2Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the sameINT INST CANCER IMMUNOLOGY INC·Filed 2013·Granted Mar 3, 2015·5 cites·12 claims
- 0992US8945578B2Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the sameINT INST CANCER IMMUNOLOGY INC·Filed 2013·Granted Feb 3, 2015·5 cites·12 claims
- 1092US8933038B2Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the sameINT INST CANCER IMMUNOLOGY INC·Filed 2013·Granted Jan 13, 2015·5 cites·12 claims
- 1191US11707512B2Cancer vaccine compositionINT INST CANCER IMMUNOLOGY INC·Filed 2019·Granted Jul 25, 2023·2 cites·20 claims
- 1291US10426822B2Cancer vaccine compositionINT INST CANCER IMMUNOLOGY INC·Filed 2016·Granted Oct 1, 2019·6 cites·17 claims
- 1391US7342092B2Cancer antigen peptide formulationsINT INST CANCER IMMUNOLOGY INC·Filed 2003·Granted Mar 11, 2008·33 cites·7 claims
- 1490US10759840B2Cancer antigen helper peptideINT INST CANCER IMMUNOLOGY INC·Filed 2017·Granted Sep 1, 2020·2 cites·10 claims
- 1590US9272026B2HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the sameINT INST CANCER IMMUNOLOGY INC·Filed 2013·Granted Mar 1, 2016·9 cites·2 claims
- 1688US10525096B2Immunotherapy for angiogenic diseaseINT INST CANCER IMMUNOLOGY INC·Filed 2015·Granted Jan 7, 2020·2 cites·6 claims
- 1787US7378384B2WT1 substitution peptidesINT INST CANCER IMMUNOLOGY INC·Filed 2003·Granted May 27, 2008·22 cites·6 claims
- 1886US10648036B2Receptor gene for peptide cancer antigen-specific T cellINT INST CANCER IMMUNOLOGY INC·Filed 2015·Granted May 12, 2020·3 cites·8 claims
- 1986US9119801B2Cancer vaccine compositionINT INST CANCER IMMUNOLOGY INC·Filed 2013·Granted Sep 1, 2015·5 cites·5 claims
- 2085US10669584B2Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of themINT INST CANCER IMMUNOLOGY INC·Filed 2014·Granted Jun 2, 2020·2 cites·8 claims
- 2183US10124046B2HLA-DR-binding antigen peptide derived from WT1INT INST CANCER IMMUNOLOGY INC·Filed 2013·Granted Nov 13, 2018·4 cites·26 claims
- 2281US9765114B2Method for cancer immunotherapyINT INST CANCER IMMUNOLOGY INC·Filed 2016·Granted Sep 19, 2017·2 cites·5 claims
- 2379US2022313770A1Immunotherapy for angiogenic diseaseINT INST CANCER IMMUNOLOGY INC·Filed 2022·Application pending·0 cites
- 2478US11413322B2Immunotherapy for angiogenic diseaseINT INST CANCER IMMUNOLOGY INC·Filed 2019·Granted Aug 16, 2022·0 cites·5 claims
- 2577US11369656B2Immunotherapy for angiogenic diseaseINT INST CANCER IMMUNOLOGY INC·Filed 2019·Granted Jun 28, 2022·0 cites·6 claims
- 2677US9539299B2Combination therapy with WT1 peptide vaccine and temozolomideINT INST CANCER IMMUNOLOGY INC·Filed 2012·Granted Jan 10, 2017·2 cites·4 claims
- 2777US9273148B2Method for cancer immunotherapyINT INST CANCER IMMUNOLOGY INC·Filed 2013·Granted Mar 1, 2016·2 cites·6 claims
- 2876US11732018B2Cancer antigen helper peptideINT INST CANCER IMMUNOLOGY INC·Filed 2020·Granted Aug 22, 2023·0 cites·12 claims
- 2972US11027003B2HLA-DR-binding antigen peptide derived from WT1INT INST CANCER IMMUNOLOGY INC·Filed 2018·Granted Jun 8, 2021·0 cites·5 claims
- 3069US2021017599A1Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of themINT INST CANCER IMMUNOLOGY INC·Filed 2020·Application pending·0 cites
- 3168US11555814B2Method for activation of helper t cell and composition for use in the methodINT INST CANCER IMMUNOLOGY INC·Filed 2018·Granted Jan 17, 2023·0 cites·2 claims
- 3267US11091531B2Antigen-specific helper T-cell receptor genesINT INST CANCER IMMUNOLOGY INC·Filed 2018·Granted Aug 17, 2021·0 cites·1 claims
- 3363US10815288B2Antigen-specific helper T-cell receptor genesINT INST CANCER IMMUNOLOGY INC·Filed 2013·Granted Oct 27, 2020·0 cites·1 claims
- 3463US2024374696A1Pharmaceutical composition and method for treating or preventing cancerINT INST CANCER IMMUNOLOGY INC·Filed 2022·Application pending·0 cites
- 3562US2021070832A1Antigen-specific helper t-cell receptor genesINT INST CANCER IMMUNOLOGY INC·Filed 2020·Application pending·0 cites
- 3660US2016243209A1Tumor antigen based on products of the tumor suppressor gene wt1INT INST CANCER IMMUNOLOGY INC·Filed 2016·Application pending·0 cites
- 3759US2018064795A1Hla-a* 1101-restricted wt1 peptide and pharmaceutical composition comprising the sameINT INST CANCER IMMUNOLOGY INC·Filed 2017·Application pending·0 cites
- 3858US12440546B2Composition for preventing or treating benign tumorINT INST CANCER IMMUNOLOGY INC·Filed 2019·Granted Oct 14, 2025·0 cites·28 claims
- 3958US12415833B2Method for activating helper T cellINT INST CANCER IMMUNOLOGY INC·Filed 2020·Granted Sep 16, 2025·0 cites·8 claims
- 4058US2008070835A1Hla-Dr-Binding Antigen Peptide Derived From Wt1INT INST CANCER IMMUNOLOGY INC·Filed 2004·Application pending·0 cites
- 4157US2009263409A1Cancer antigen peptide formulationsINT INST CANCER IMMUNOLOGY INC·Filed 2007·Application pending·0 cites
- 4256US2019111120A1Novel cancer antigen eef2INT INST CANCER IMMUNOLOGY INC·Filed 2018·Application pending·0 cites
- 4356US2013196427A1Cancer antigen peptides derived from wt1INT INST CANCER IMMUNOLOGY INC·Filed 2013·Application pending·0 cites
- 4454US2016176939A1Cancer antigen helper peptideINT INST CANCER IMMUNOLOGY INC·Filed 2016·Application pending·0 cites
- 4554US2016367649A1Cancer vaccine compositionINT INST CANCER IMMUNOLOGY INC·Filed 2015·Application pending·0 cites
- 4654US2016199472A1Hla-a* 1101-restricted wt1 peptide and pharmaceutical composition comprising the sameINT INST CANCER IMMUNOLOGY INC·Filed 2016·Application pending·0 cites
- 4752US10383925B2Cancer antigen EEF2INT INST CANCER IMMUNOLOGY INC·Filed 2015·Granted Aug 20, 2019·0 cites·3 claims
- 4849US2017072038A1Combination therapy with wt1 peptide vaccine and temozolomideINT INST CANCER IMMUNOLOGY INC·Filed 2016·Application pending·0 cites
- 4947US2017138958A1Method for measuring anti-wt1 antibodyINT INST CANCER IMMUNOLOGY INC·Filed 2016·Application pending·0 cites
- 5045US10408840B2Method for predicting clinical effect of immunotherapyINT INST CANCER IMMUNOLOGY INC·Filed 2014·Granted Sep 10, 2019·0 cites·27 claims
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when INT INST CANCER IMMUNOLOGY INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →